Sanofi and AstraZeneca’s Beyfortus enters hot RSV space

The European Commission (EC) has approved Beyfortus (nirsevimab)
for the prevention of respiratory syncytial virus (RSV) lower
respiratory tract disease in newborns and infants during their
first RSV season.

Beyfortus - which is being developed jointly by Sanofi (Euronext:
SAN) and AstraZeneca (LSE: AZN) - is the first and only
single-dose RSV protective option for the broad infant
population, including those born healthy, at term or preterm, or

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.


Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.

Source link